| Literature DB >> 24552493 |
Frank J Bove1, Perri Zeitz Ruckart, Morris Maslia, Theodore C Larson.
Abstract
BACKGROUND: Two drinking water systems at U.S. Marine Corps Base Camp Lejeune, North Carolina were contaminated with solvents during 1950s-1985.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24552493 PMCID: PMC3943370 DOI: 10.1186/1476-069X-13-10
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
Estimated monthly average contaminant concentrations in the Tarawa Terrace system, 1975 – 1985
| Tetrachloroethylene | 75.7 | 84.9 | 0 – 158.1 | 117 | 16 |
| Trichloroethylene | 3.1 | 3.5 | 0 – 6.6 | 11 | 0 |
| Vinyl chloride | 5.6 | 6.2 | 0 – 12.3 | 117 | 0 |
| Tetrachloroethylene | 68.3 | 68.2 | 43.8 – 94.8 | 60 | 0 |
| Trichloroethylene | 2.8 | 2.9 | 1.7 – 3.9 | 0 | 0 |
| Vinyl chloride | 5.2 | 5.5 | 2.6 – 7.3 | 60 | 0 |
| Tetrachloroethylene | 96.1 | 95.5 | 0¥ – 158.1 | 57 | 16 |
| Trichloroethylene | 3.9 | 3.9 | 0¥ – 6.6 | 11 | 0 |
| Vinyl chloride | 7.0 | 7.0 | 0¥ – 12.3 | 57 | 0 |
*Two contaminated wells were shut down in January 1985. Estimated monthly average tetrachloroethylene levels from February through December 1985 were <4 μg/L.
¥One contaminated well was shut down for maintenance during 7/80 – 8/80 and 1/83 – 2/83. The other contaminated well was not in use until August 1984.
Estimated monthly average contaminant concentrations in the Hadnot Point system, 1975 – 1985
| Tetrachloroethylene | 15.7 | 15.4 | 0 – 38.7 | 111 | 0 |
| Trichloroethylene | 358.7 | 365.9 | 0 – 783.3 | 122 | 113 |
| Vinyl chloride | 24.0 | 22.2 | 0 – 67.3 | 122 | 0 |
| Benzene | 5.4 | 4.6 | 0 – 12.2 | 63 | 0 |
| Tetrachloroethylene | 12.2 | 12.0 | 1.4 – 24.1 | 53 | 0 |
| Trichloroethylene | 325.1 | 327.7 | 60.6 – 546.3 | 60 | 55 |
| Vinyl chloride | 17.3 | 16.5 | 2.3 – 33.4 | 60 | 0 |
| Benzene | 3.5 | 3.4 | 0 – 5.8 | 4 | 0 |
| Tetrachloroethylene | 21.5 | 21.4 | 2.2 – 38.7 | 58 | 0 |
| Trichloroethylene | 449.2 | 446.2 | 42.6 – 783.3 | 62 | 58 |
| Vinyl chloride | 34.3 | 35.7 | 4.2 – 67.3 | 62 | 0 |
| Benzene | 7.6 | 7.6 | 1.6 – 12.2 | 59 | 0 |
*Contaminated wells were shut down after February 1985. From March through December 1985, estimated monthly average levels of trichloroethylene, tetrachloroethylene and vinyl chloride were <1 μg/L, and benzene was <4 μg/L.
Figure 1Camp Lejeune cohort exposure assessment. *8th Marines (both enlisted and officers) moved to Camp Geiger (an unexposed area) by 1980. **BOQ = Bachelor officer quarters (Note: BOQs elsewhere on base were in unexposed areas).
Demographics of the Camp Lejeune and Camp Pendleton cohorts
| Male | 94.8% | 96.4% |
| Female | 5.2% | 3.6% |
| “White” | 73.1% | 77.6% |
| African American | 24.2% | 17.0% |
| “other” or unknown | 2.7% | 5.4% |
| Median age, start of follow-up | 20 | 20 |
| Median age, end of follow-up | 49 | 49 |
| % ≥55 yrs, end of follow-up | 2.7% | 3.2% |
| Not a high school graduate | 11.3% | 14.7% |
| High school graduate | 84.9% | 80.5% |
| College graduate | 3.8% | 4.8% |
| Enlisted | 96.4% | 95.5% |
| Officer | 3.6% | 4.5% |
| Median months active duty service | 36 | 35 |
| Total deaths | 8,964 (5.8%) | 9,365 (6.0%) |
| % deaths occurring >1995 | 55.5% | 54.7% |
| Total lost to follow-up | 1,990 (1.3%) | 2,339 (1.5%) |
| Total person-years of follow-up | 4.14 million | 4.19 million |
Standardized mortality ratios (SMRs), underlying cause of death
| Cause of death | Obs. | Exp. | SMR (95% CI) | Obs. | Exp. | SMR (95% CI) |
| All causes | 9,365 | 10,922 | 0.86 (0.84, 0.87) | 8,964 | 10,864 | 0.83 (0.81, 0.84) |
| All cancers | 1,008 | 1,296 | 0.78 (0.73, 0.83) | 1,078 | 1,272 | 0.85 (0.80, 0.90) |
| Diseases of primary interest | ||||||
| Kidney cancer | 33 | 37.20 | 0.89 (0.61, 1.25) | 42 | 36.08 | 1.16 (0.84, 1.57) |
| Bladder cancer | 14 | 13.65 | 1.03 (0.56, 1.72) | 11 | 13.04 | 0.84 (0.42, 1.51) |
| Liver* cancer | 39 | 69.21 | 0.56 (0.40, 0.77) | 51 | 69.20 | 0.74 (0.55, 0.97) |
| Esophageal cancer | 27 | 43.33 | 0.62 (0.41, 0.91) | 35 | 41.34 | 0.85 (0.59, 1.18) |
| Hematopoietic cancers | 167 | 215.93 | 0.77 (0.66, 0.90) | 165 | 211.10 | 0.78 (0.67, 0.91) |
| Hodgkin | 23 | 25.86 | 0.89 (0.56, 1.33) | 24 | 25.03 | 0.96 (0.61, 1.43) |
| NHL** | 68 | 87.56 | 0.78 (0.60, 0.98) | 58 | 85.50 | 0.68 (0.52, 0.88) |
| Multiple myeloma | 12 | 16.26 | 0.74 (0.38, 1.29) | 17 | 16.13 | 1.05 (0.61, 1.69) |
| Leukemias | 64 | 86.26 | 0.74 (0.57, 0.95) | 66 | 84.43 | 0.78 (0.60, 0.99) |
| Cervical cancer | 2 | 3.53 | 0.57 (0.07, 2.05) | 5 | 4.88 | 1.03 (0.33, 2.39) |
| Pancreatic cancer | 44 | 60.05 | 0.73 (0.53, 0.98) | 57 | 58.29 | 0.98 (0.74, 1.27) |
| Colon cancer | 73 | 93.28 | 0.78 (0.61, 0.98) | 86 | 92.29 | 0.93 (0.75, 1.15) |
| Rectal cancer | 16 | 29.84 | 0.54 (0.31, 0.87) | 24 | 29.54 | 0.81 (0.52, 1.21) |
| Soft tissue cancers | 21 | 27.82 | 0.75 (0.47, 1.15) | 29 | 27.44 | 1.06 (0.71, 1.52) |
| Brain cancer | 80 | 93.36 | 0.86 (0.68, 1.07) | 74 | 88.95 | 0.83 (0.65, 1.04) |
| Laryngeal cancer | 13 | 12.15 | 1.07 (0.57, 1.83) | 6 | 11.92 | 0.50 (0.18, 1.10) |
| Lung*** cancer | 216 | 265.44 | 0.81 (0.71, 0.93) | 237 | 259.01 | 0.92 (0.80, 1.04) |
| Oral cancers**** | 35 | 37.64 | 0.93 (0.65, 1.29) | 26 | 37.38 | 0.70 (0.45, 1.02) |
| Breast (female) cancer | 7 | 14.68 | 0.48 (0.19, 0.98) | 10 | 19.62 | 0.51 (0.24, 0.94) |
| Prostate cancer | 15 | 10.68 | 1.41 (0.79, 2.32) | 18 | 10.41 | 1.73 (1.02, 2.73) |
| Liver diseases | 233 | 322.70 | 0.72 (0.63, 0.82) | 191 | 311.90 | 0.61 (0.53, 0.71) |
| Kidney diseases | 37 | 71.72 | 0.52 (0.37, 0.71) | 37 | 74.54 | 0.50 (0.35, 0.68) |
| ALS | 27 | 19.42 | 1.39 (0.92, 2.02) | 21 | 18.45 | 1.14 (0.70, 1.74) |
| Multiple sclerosis | 10 | 14.95 | 0.67 (0.32, 1.23) | 12 | 14.75 | 0.81 (0.42, 1.42) |
| Stomach cancer | 29 | 41.43 | 0.70 (0.47, 1.01) | 35 | 41.88 | 0.84 (0.58, 1.16) |
| Cardiovascular disease† | 1,376 | 1,791 | 0.77 (0.73, 0.81) | 1,390 | 1,781 | 0.78 (0.74, 0.82) |
| COPD | 45 | 55.82 | 0.81 (0.59, 1.08) | 47 | 53.89 | 0.87 (0.64, 1.16) |
Not evaluated due to small numbers were Parkinson’s disease and male breast cancer.
*Biliary passages, liver and gall bladder **Non-Hodgkin lymphoma.
***Trachea, bronchus, and lung ****Oral cavity and Pharynx.
†Includes diseases of the heart and other diseases of the circulatory system.
Camp Lejeune = 154,932; person-years = 4,140,042.
Camp Pendleton = 154,969; person-years = 4,190,132.
Camp Lejeune vs Camp Pendleton: hazard ratios and 95% confidence intervals, adjusted by sex, race, rank and education, 10-year lag
| All cancers | 1.10 | 0.02 | ||
| Kidney cancer | 1.35 | 0.19 | ||
| Bladder cancer | 0.76 | 0.50 | ||
| Liver* cancer | 1.42 | 0.11 | ||
| Esophageal cancer | 1.43 | 0.17 | ||
| Hematopoietic cancers | 1.05 | 0.57 | ||
| Hodgkin | 1.47 | 0.26 | ||
| NHL** | 0.81 | 0.43 | ||
| Multiple myeloma | 1.68 | 0.21 | ||
| Leukemias | 1.11 | 0.63 | ||
| Cervical cancer | 1.33 | 0.74 | ||
| Pancreatic cancer | 1.36 | 0.13 | ||
| Colorectal cancers | 1.13 | 0.35 | ||
| Colon cancer | 1.04 | 0.76 | ||
| Rectal cancer | 1.60 | 0.15 | ||
| Soft tissue cancers | 1.38 | 0.30 | ||
| Brain cancer | 0.93 | 0.84 | ||
| Laryngeal cancer | 0.54 | 0.22 | ||
| Lung*** cancer | 1.16 | 0.10 | ||
| Oral cancers**** | 0.82 | 0.46 | ||
| Breast (female) cancer | 0.93 | 0.88 | ||
| Prostate cancer | 1.23 | 0.57 | ||
| Liver diseases | 0.87 | 0.18 | ||
| Kidney diseases | 1.00 | 0.95 | ||
| ALS | 0.83 | 0.54 | ||
| Multiple sclerosis | 1.21 | 0.65 | ||
| Stomach cancer | 1.15 | 0.58 | ||
| Cardiovascular disease† | 1.04 | 0.31 | ||
| COPD | 1.08 | 0.70 | ||
Not evaluated due to small numbers were Parkinson’s disease, male breast cancer, and aplastic anemia.
LCL: lower confidence limit UCL: upper confidence limit.
*Biliary passages, liver and gall bladder ***Trachea, bronchus, and lung.
****Oral cavity and Pharynx.
†Includes heart diseases and other diseases of the circulatory system.
Categorization of cumulative exposure variables (μg/L –months) within the Camp Lejeune cohort
| ≤ 1 | >1 - 155 | >155 - 380 | >380 – 8,585 | |
| 66, 582 (43.0%) | 28,230 (18.2%) | 27,255 (17.6%) | 32,865 (21.2%) | |
| ≤ 1 | >1 – 3,100 | >3,100 – 7,700 | >7,700 – 39,745 | |
| 64, 584 (41.7%) | 31,069 (20.1%) | 27,638 (17.8%) | 31,641 (20.4%) | |
| ≤ 1 | >1 - 205 | >205 - 500 | >500 – 2,800 | |
| 66, 470 (42.9%) | 27,651 (17.8%) | 28,063 (18.1%) | 32,748 (21.1%) | |
| < 2 | 2 - 45 | >45 - 110 | >110 - 601 | |
| 64, 580 (41.7%) | 24,579 (15.9%) | 31,838 (20.5%) | 33,935 (21.9%) | |
| ≤ 1 | >1 – 4,600 | >4,600 – 12,250 | >12,250 - 64,016 | |
| 57, 328 (37.0%) | 35,432 (22.9%) | 29,687 (19.2%) | 32,485 (21.0%) | |
*An individual’s maximum amount of cumulative exposure (μg/L –months) at the end of follow-up.
N = 154,932.
Hazard ratios (95% CI) for categorical cumulative exposure, and coefficients (95% CI) for continuous cumulative exposure
| PCE | 1.40 (0.54, 3.58) N=8 | 1.82 (0.75, 4.42) N=11 | 1.59 (0.66, 3.86) N=11 | .00009 (-0.00048, 0.00065), p=.76 | .0813 (-0.0553, 0.2179), p=.24 |
| TVOC | 1.42 (0.58, 3.47) N=10 | 1.44 (0.58, 3.59) N=10 | 1.54 (0.63, 3.75) N=11 | .00001 (-0.00003, 0.00005) p=.59 | .0633 (-0.0481, 0.1747) p=.26 |
| TCE | 1.52 (0.42, 5.59) N=4 | 1.63 (0.43, 6.12) N=4 | 1.97 (0.55, 7.03) N=5 | .00005 (-0.00003, 0.00013) p=.20 | .0940 (-0.0650, 0.2530) p=.25 |
| VC | 1.20 (0.29, 4.94) N=3 | 2.07 (0.59, 7.27) N=5 | 1.99 (0.56, 7.13) N=5 | .00056 (-0.00060, 0.00172) p=.34 | .1101 (-0.0817, 0.3019) p=.26 |
| Benzene | 1.24 (0.30, 5.11) N=3 | 1.88 (0.54, 6.61) N=5 | 1.94 (0.54, 6.95) N=5 | .00203 (-0.00339, 0.00745) p=.46 | .1074 (-0.1088, 0.3236) p=.33 |
| TVOC | 0.66 (0.13, 3.39) N=2 | 1.77 (0.50, 6.25) N=5 | 2.17 (0.63, 7.50) N=6 | .00003 (-0.00003, 0.00009) p=.24 | .0752 (-0.0818, 0.2322) p=.35 |
| TCE | 2.00 (1.00, 4.00) N=16 | 1.54 (0.71, 3.36) N=11 | 1.81 (0.85, 3.85) N=13 | .00002 (-0.00004, 0.00008) p=.46 | .0801 (-0.0093, 0.1695) p=.08 |
| Benzene | 2.54 (1.27, 5.08) N=17 | 1.46 (0.66, 3.20) N=11 | 1.69 (0.77, 3.67) N=12 | .00168 (-0.00158, 0.00494) p=.31 | .1276 (0.0020, 0.2532) p=.05 |
| TVOC | 2.50 (1.24, 5.03) N=19 | 1.33 (0.56, 3.14) N=9 | 2.33 (1.08, 5.03) N=15 | .00001 (-0.00003, 0.00005) p=.44 | .0950 (0.0032, 0.1868) p=.04 |
| TCE | 0.91 (0.25, 3.23) N=4 | 0.87 (0.21, 3.57) N=3 | 1.93 (0.65, 5.79) N=8 | .00007 (0.00001, 0.00013) p=.04 | .0436 (-0.1083, 0.1955) p=.57 |
| PCE | 0.69 (0.13, 3.55) N=2 | 1.58 (0.45, 5.50) N=5 | 1.96 (0.64, 6.02) N=8 | .00039 (-0.00002, 0.00080) p=.06 | .0836 (-0.1060, 0.2732) p=.39 |
| VC | 1.22 (0.33, 4.51) N=4 | 0.91 (0.22, 3.87) N=3 | 2.21 (0.71, 6.86) N=8 | .00110 (0.00020, 0.00200) p=.02 | .0724 (-0.1149, 0.2597) p=.45 |
| TVOC | 1.27 (0.37, 4.41) N=5 | 0.89 (0.21, 3.82) N=3 | 2.11 (0.67, 6.68) N=8 | .00005 (0.00001, 0.00009) p=.03 | .0702 (-0.0872, 0.2276) p=.38 |
TCE: Trichloroethylene PCE: Tetrachloroethylene (or perchloroethylene) VC: Vinyl chloride.
TVOC: (“total volatile organic compounds”) the sum of all contaminants (TCE, PCE, trans-1,2-dichloroethylene, vinyl chloride and benzene) in the drinking water.
The referent group for each contaminant consists of those Camp Lejeune cohort members with cumulative exposures within the reference level for that contaminant shown in Table 6.
Exposure lagged 10 years. Adjusted for race, sex, rank and education. Selected causes of death. Camp Lejeune cohort (N = 154,932).